Amarin Corporation plc AMRN
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -13.25%
- 1 year
- -26.16%
- Open
- 12.71
- Prev close
- 12.74
- Mkt cap
- 509.13M
- Vol
- 100.03K
- Avg vol
- 68.64K
- EPS
- -0.80
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 12.00
- High
- 12.73
- Forward P/E
- -2.17
- Beta
- 1.93
- Short ratio
- 12.75
- Inst. own
- 17.05%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.5324
- 200-d avg
- 0.70385
- 1y target
- 1.00
5D chart
Signals (97)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 3:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 2 days ago |
| RSI: Oversold | Oct 30, 2:50 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:00 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:55 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 11:55 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:40 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:35 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:45 AM | 2 days ago |
| RSI: Oversold | Oct 30, 10:05 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:45 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:45 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:45 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:40 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 3 days ago |
| RSI: Oversold | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:15 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:50 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:15 AM | 3 days ago |
| RSI: Overbought | Oct 29, 11:15 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 4:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:55 PM | 4 days ago |
| RSI: Overbought | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:25 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:55 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:55 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:45 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:45 PM | 5 days ago |
| RSI: Oversold | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 11:15 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 4:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:45 PM | 6 days ago |
| RSI: Overbought | Oct 26, 3:40 PM | 6 days ago |
| RSI: Overbought | Oct 26, 3:25 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:45 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 10:45 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:25 AM | 6 days ago |
News
3 days ago zacks.com
Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark
AMRN's Q3 2026 earnings surpass estimates despite declining revenues. Global Vascepa/Vazkepa demand grows 55% and cash reserves increase.
4 days ago seekingalpha.com
Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript
Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript
4 days ago marketbeat.com
What Amarin (AMRN) Said on Its Q3 Earnings Call
Amarin NASDAQ: AMRN reported its first profitable quarter in two years for the third quarter of 2026, as lower operating expenses, positive operating cash flow and growth in international in-market…
4 days ago benzinga.com
Amarin Corp Q3 2026 Earnings Call Transcript
Amarin Corp (NASDAQ:AMRN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
-
4 days ago benzinga.com
Amarin Corp Q3 Adj. EPS $0.08 Beats $(0.02) Estimate, Sales $39.550M Miss $43.711M Estimate
Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.02) by 500 percent. This is a 57.89 percent decrease over earnings of $0.19…
4 days ago globenewswire.com
Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income
DUBLIN and BRIDGEWATER, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today…
1 week ago globenewswire.com
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
Pre-specified and Statistically Powered Key Endpoints Included Progression-free Survival (PFS) and Overall Survival (OS). Although Primary Endpoint of PFS Was Not Met, The Key Secondary Endpoint of…
1 week ago globenewswire.com
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026
DUBLIN and BRIDGEWATER, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that…
1 month ago defenseworld.net
Head-To-Head Survey: Amarin (NASDAQ:AMRN) and SCYNEXIS (NASDAQ:SCYX)
Amarin (NASDAQ: AMRN - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies…
1 month ago defenseworld.net
Analyzing Amarin (NASDAQ:AMRN) & Elanco Animal Health (NYSE:ELAN)
Elanco Animal Health (NYSE: ELAN - Get Free Report) and Amarin (NASDAQ: AMRN - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies…
1 month ago zacks.com
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.
2 months ago globenewswire.com
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA)
2 months ago globenewswire.com
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients
DUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today…
2 months ago globenewswire.com
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced…
-
2 months ago benzinga.com
JP Morgan Reinstates Underweight on Amarin Corp, Announces $13 Price Target
JP Morgan analyst Jessica Fye reinstates Amarin Corp (NASDAQ:AMRN) with a Underweight and announces $13 price target.
3 months ago seekingalpha.com
Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript
Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript
3 months ago zacks.com
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short
AMRN surpasses Q2 earnings estimates despite lower revenues, as cost cuts, rising demand and global partner-driven growth shape its ongoing transformation.
3 months ago marketbeat.com
Amarin Q2 Earnings Call Highlights
Amarin NASDAQ: AMRN said its second-quarter results reflected progress in its dual commercial strategy, which combines a company-managed U.S. business with partnered commercialization…
-
3 months ago benzinga.com
Amarin Corp Q2 Sales $42.211M Miss $44.550M Estimate
Amarin Corp (NASDAQ:AMRN) reported quarterly sales of $42.211 million which missed the analyst consensus estimate of $44.550 million by 5.25 percent. This is a 41.97 percent decrease over sales of…
3 months ago globenewswire.com
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA's…
3 months ago globenewswire.com
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
DUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today…
3 months ago zacks.com
Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' Now
Amarin (AMRN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a…
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.4 billion. Bluejay…
-
4 months ago benzinga.com
Amarin Highlights Recent FDA Approval Of Injectable Apolipoprotein C-III Therapies For Treatment Of Severe Hypertriglyceridemia, Defined As Triglycerides Greater Than Or Equal To 500 mg/dL
Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, applauds the recent FDA approval of injectable apolipoprotein C-III (APOC3)…
4 months ago globenewswire.com
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
Clinically Validated, Increasingly Prescribed, Widely Reimbursed, and Affordable, VASCEPA Expected to Benefit from Increased Attention to Patients with Severely Elevated Triglycerides Clinically…
4 months ago zacks.com
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
Here is how Amarin (AMRN) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
-
5 months ago benzinga.com
U.S. Supreme Court Rules In Favor Of Hikma Pharmaceuticals V Amarin Pharmaceuticals Over Patent Infringement Claims By Amarin
https://www.supremecourt.gov/opinions/25pdf/24-889_5i36.pdf
-
5 months ago benzinga.com
Amarin Announces New Data From A Post Hoc Analysis Of The REDUCE-IT Trial; Apolipoprotein B More Effectively Identified Individuals At Increased Residual Cardiovascular Risk
Amarin Corporation plc (NASDAQ:AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced new data from a post hoc analysis of the…
6 months ago benzinga.com
Earnings Scheduled For April 29, 2026
Earnings Scheduled For April 29, 2026
-
6 months ago benzinga.com
Amarin Corp Q1 Sales $45.132M Beat $43.771M Estimate
Amarin Corp (NASDAQ:AMRN) reported quarterly sales of $45.132 million which beat the analyst consensus estimate of $43.771 million by 3.11 percent. This is a 7.41 percent increase over sales of…
-
7 months ago benzinga.com
Amarin Highlights 2026 ACC/AHA Dyslipidemia Guideline Emphasizing CV Risk Management In Hypertriglyceridemia
Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the recommendation that the treatment of CV risk in…
-
8 months ago benzinga.com
Amarin Published Data In The European Journal Of Preventive Cardiology Showing That VASCEPA Was Associated With Fewer Hospitalizations In A REDUCE-IT Analysis
Peer-reviewed paper indicates icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects…
8 months ago benzinga.com
Amarin Corp Q4 2025 Earnings Call Transcript
Amarin Corp Q4 2025 Earnings Call Transcript
8 months ago benzinga.com
Amarin Corp Earnings Report: Q4 Overview
Amarin Corp Earnings Report: Q4 Overview
-
8 months ago benzinga.com
Amarin Corp Q4 Adj. EPS $0.01 Beats $(0.56) Estimate, Sales $49.219M Miss $50.619M Estimate
Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.56) by 101.79 percent. This is a 150 percent increase over losses of $(0.02)…
-
8 months ago benzinga.com
Earnings Scheduled For February 25, 2026
Earnings Scheduled For February 25, 2026
1 year ago benzinga.com
Earnings Scheduled For October 29, 2025
Earnings Scheduled For October 29, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
1 year ago benzinga.com
Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday
Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday
1 year ago benzinga.com
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
-
2 years ago benzinga.com
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
2 years ago benzinga.com
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.
-
2 years ago benzinga.com
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
-
2 years ago benzinga.com
Why TechTarget Shares Are Trading Higher By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of TechTarget, Inc. (NASDAQ: TTGT) rose sharply during Thursday’s session after the company announced a strategic combination with Informa Tech's digital businesses. TechTarget shares surged…
-
2 years ago benzinga.com
Aspen Aerogels Issues Business Update, Joins Plug Power, SunPower And Other Big Stocks Moving Lower On Thursday
U.S. stocks traded lower, with the Dow Jones index falling over 150 points on Thursday. Shares of Aspen Aerogels, Inc. (NYSE: ASPN) fell sharply during Thursday’s session after the company issued a…
-
3 years ago benzinga.com
Earnings Scheduled For November 1, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.